Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Lactobacillus rhamnosus HN001 and Reduced Prevalence of Rhinoconjunctivitis

Doses used in studies

CFU/day: 6 billion (median 6 billion, IQR 6 billion–6 billion) — 1 study

Safety in these studies

Overall tolerabilityReported
This study showed that the protective effect of HN001 against eczema... extended to at least 4 years of age.
from: A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years o

1 of 1 paper

A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years
- 2012-06-15
- RCT
- Clinical & Experimental Allergy 42(7)
- - K. Wickens
  - Peter N. Black
  - Thorsten Stanley
  - Edwin A. Mitchell
  - C. Barthow
  - P. Fitzharris
  - Gordon Purdie
  - Julian Crane
- PubMed: 22702506
- DOI: 10.1111/j.1365-2222.2012.03975.x
6 Insights on
- Reduced Prevalence of Rhinoconjunctivitis
- High evidence
- Highly Cited
prevalence of rhinoconjunctivitis at 4 years (Relative risk 0.38 (95% CI 0.18-0.83)) were significantly reduced in the children taking HN001
Effect
Beneficial
Effect size
Large
Significant
Yes
Dose
6 × 10^9 cfu/day